drive tumor infiltrating t cell expansion in
play

TLR9 agonist harnesses innate immunity to drive tumor-infiltrating T-cell expansion in distant lesions in a phase 1/2 study of intratumoral IMO-2125+ipilimumab in anti- PD1 refractory melanoma patients Cara Haymaker, PhD Presenter Disclosure

0 downloads 3 Views 1,77 MB Size Report
  1. TLR9 agonist harnesses innate immunity to drive tumor-infiltrating T-cell expansion in distant lesions in a phase 1/2 study of intratumoral IMO-2125+ipilimumab in anti- PD1 refractory melanoma patients Cara Haymaker, PhD

  2. Presenter Disclosure Information Cara Haymaker The following relationships exist related to this presentation: No Relationships to Disclose

  3. Modulation of the tumor microenvironment by intratumoral administration of the TLR9 agonist IMO-2125 Intratumoral administration of IMO-2125 1. TLR9 induction of IFN a and APC maturation 2. TIL Activation and Proliferation TAM CD8 + TIL mDC1 IFN a pDC Improved antigen presentation B cell results in TIL activation and B cell proliferation Activation of APCs to improve T-cell priming

  4. Trial Design (NCT02644967) Intratumoral IMO-2125 Ipilimumab i.t. IMO-2125 alone i.t. IMO-2125 + Ipilimumab 1 2 3 4 5 6 7 8 9 10 11 12 13 Week Cycle 1 Cycle 2 Cycle 3 Cycle 4

  5. Dose-finding phase : IMO-2125 + Ipilimumab  18 subjects treated with IMO-2125 doses from 4 – 32 mg (with standard ipilimumab)  Patient population was refractory to PD-1 inhibitors and had a high frequency of visceral metastases (M1c; 72%)  Patients were injected in a single focus of tumor; deep visceral injections were permitted  Safety:  No DLT, treatment-related deaths or discontinuations from therapy  Immune-related AE were similar to ipilimumab monotherapy  RP2D selected as IMO-2125 8 mg with standard ipilimumab  Efficacy (RP2D population):  5/10 patients had either confirmed (4) or unconfirmed (1) RECIST response ( BOR = 50% ), including 1 durable CR (> 1 year)  Another 2 subjects had durable SD (>6 mos)  Clinical benefit rate = 67%  1 additional durable PR (> 1 year) at the 4 mg IMO-2125 dose level Diab, ESMO 2017

  6. Early response data to IMO-2125 + Ipilimumab Data cut off: 3 Nov 2017

  7. Image-guided intratumoral injection of deep lesions with IMO-2125 CT guided Intratumoral injection of deep inguinal soft tissue mass

  8. Tumor Imaging of Patient with a Partial Response: Ipilimumab + i.t. IMO-2125 (8mg) Pre-Therapy Post-Therapy Injected Lesion Distant Lesion

  9. Immune response monitoring to correlate with mechanism of action Injected = Injected lesion Week 8 Distant = Un-injected Lesion 24 hours post i.t. 5 doses of IMO-2125 and 3 Ipilimumab IMO-2125 injection doses of Ipi Pre-dose = collection of biopsy = collection of PBMCs C1W2 C2W5 C3W8 C4W11 Injected Distant Injected Injected Distant Tumor Core Formalin - IHC Needle biopsy Fresh flow cytometry DC subsets and maturation Injected Immune infiltrate changes Distant T cell activation/functional state DNA and RNA (TCRseq and gene expression)

  10. Induction of IFN a -response gene signature after i.t. IMO-2125 IFIT1 MX1 IRF7 IFIT2 TAP1 TAP2 p <0.01 p <0.0001 p <0.05 predose 24hr n=15

  11. Rapid mDC1 maturation and macrophage influx induced by IMO-2125 in the tumor Nanostring Flow cytometry 1 0 0 p= 0.07 % H L A -D R o n m D C 1 c e lls 8 0 6 0 4 0 2 0 0 predose 24hr p r e d o s e 2 4 h r n=15 n=12 CD84, CD163, CD64

  12. Combination therapy induces CD8 + TIL activation early on-treatment in responding patients Activation at C3W8 by Nanostring Pre-dose C3W8 n=13 CXCL9 Injected Distant Injected Distant (A) (B) CD27 CD3 CD8 CD86 IL12 IL2 TBX21 IFNG CD80 PD-L1

  13. Combination therapy induces CD8 + TIL activation early on-treatment in responding patients Activation at C3W8 by Nanostring Pre-dose C3W8 n=13 CXCL9 Injected Distant Injected Distant (A) (B) CD27 CD3 CD8 CD86 IL12 IL2 TBX21 IFNG CD80 PD-L1

  14. Combination therapy induces CD8 + TIL proliferation and CTL function (A) (B) Proliferation by flow cytometry Distant Lesion 1 0 0 p= 0.11 % K i6 7 o n C D 8 + T c e lls 8 0 6 0 4 0 2 0 0 p r e d o s e C 3 W 8 n=12

  15. Combination therapy induces CD8 + TIL proliferation and CTL function Function at C3W8 by Nanostring (A) (B) n=13 Proliferation by flow cytometry HLA-C Distant Lesion HLA-A 1 0 0 p= 0.11 HLA-B % K i6 7 o n C D 8 + T c e lls 8 0 GZMM 6 0 GZMH 4 0 GNLY 2 0 GZMK 0 GZMA p r e d o s e C 3 W 8 GZMB n=12 PRF1

  16. Combination therapy induces CD8 + TIL proliferation and CTL function Function at C3W8 by Nanostring (A) (B) n=13 Proliferation by flow cytometry HLA-C Distant Lesion HLA-A 1 0 0 p= 0.11 HLA-B % K i6 7 o n C D 8 + T c e lls 8 0 GZMM 6 0 GZMH 4 0 GNLY 2 0 GZMK 0 GZMA p r e d o s e C 3 W 8 GZMB n=12 PRF1

  17. Combination therapy induces CD8 + TIL proliferation and CTL function Function at C3W8 by Nanostring (A) (B) n=13 Proliferation by flow cytometry HLA-C Distant Lesion HLA-A 1 0 0 p= 0.11 HLA-B % K i6 7 o n C D 8 + T c e lls 8 0 GZMM 6 0 GZMH 4 0 GNLY 2 0 GZMK 0 GZMA p r e d o s e C 3 W 8 GZMB n=12 PRF1

  18. Combination therapy induces CD8 + TIL proliferation and CTL function Function at C3W8 by Nanostring (A) (B) n=13 Proliferation by flow cytometry HLA-C Distant Lesion HLA-A 1 0 0 p= 0.11 HLA-B % K i6 7 o n C D 8 + T c e lls 8 0 GZMM 6 0 GZMH 4 0 GNLY 2 0 GZMK 0 GZMA p r e d o s e C 3 W 8 GZMB n=12 PRF1

  19. Preferential CD8 + T-cell proliferation at the distant lesion Time point: C3W8 1 0 0 p =0.04 % K i6 7 o n C D 8 + T c e lls 8 0 6 0 4 0 2 0 0 P B M C s tu m o r n=11

  20. Selective increase in CD8 + T-cell proliferation in the tumors of responding patients Responders Non-Responders respond = N respond = Y 100 100 00 00 tumor tumor %Ki67 + on CD8 + T cells %Ki67 + on CD8 + T cells PBMCs PBMCs 80 80 80 80 60 60 60 60 p =0.0071 40 40 40 40 p >0.05 20 20 20 20 p >0.05 p >0.05 0 0 0 0 predose 24hr C3W8

  21. Expansion of top 50 T-cell clones in the distant lesion of responding patients Pre-dose C3W8 Injected Distant Injected Distant Responders Non-Responders F re q u e n c y o f to p 5 0 c lo n e s F re q u e n c y o f to p 5 0 c lo n e s 3 0 1 0 0 8 0 2 0 6 0 4 0 1 0 2 0 0 0 p r e d o s e C 3 W 8 p r e d o s e C 3 W 8

  22. Expanding clones in the distant lesion are shared with the injected lesion No Clone shared Top 50 clones in the distant lesion at C3W8 of responding patients between lesions Yes Pt 3 Pt 8 Pt 23 Pt 25 Number = clonal specific change in frequency (C3W8 – predose) Circle size reflects the frequency of the clone relative to the other clones present

  23. Lessons and Take Home Messages • Key points – IMO-2125 induces a strong type 1 interferon gene signature, macrophage influx and robust DC maturation post injection independent of ipilimumab – Combination therapy induces CD8 + T cell proliferation and activation that is preferential to the tumor – Major T-cell clones expanding on therapy in responding patients are shared between local and distant lesions indicating that priming/reactivation is to a shared antigen • Potential impact on the field – Combining intra-tumoral DC activation to enhance T-cell priming with checkpoint blockade may be key in IO refractory patient population – A local tumor can be used as an in situ vaccine through activation of local APCs and injection of one lesion results in regression of distant lesions that may not be easily accessible • Lessons learned – On-treatment biopsy timing is critical!!

  24. Acknowledgements MDACC Idera Pharmaceutical Collaborators Adi Diab - PI Chantale Bernatchez Clayton Fletcher Marc Uemura Joanna Horobin Marihella James Sri Chunduru Salah Bentebibel Mark Cornfeld Ankit Bhatta Patients and their families Jim Geib Jason Roszik Julie Brevard Michael Tetzlaff Suzanne Swann Patrick Hwu Daqing Wang Willem Overwijk Kate Lipford Robert Doody MDACC Melanoma Medical MDACC Interventional Oncology Clinicians and Radiology Team Staff Poster #018

Recommend Documents


sinonasal smooth muscle cell tumor haemangiopericytoma
Sinonasal smooth muscle cell tumor

03 RJR 03 2011 - 0 BT-COR.qxd:Interior 6/30/11 8:09 PM Page 131 Romanian

neoplasia i tumor nomenclature tumor nomenclature lecture
Neoplasia I: Tumor Nomenclature Tumor

Neoplasia I: Tumor Nomenclature Tumor Nomenclature Lecture Objectives Define

cancer cell tumor kinetics
Cancer Cell Tumor Kinetics Claudia

Cancer Cell Tumor Kinetics Claudia Neuhauser University of Minnesota

evaluating cell lines as tumor models
Evaluating cell lines as tumor models

Evaluating cell lines as tumor models by comparison of genomic profiles

henry moon lecture
Henry Moon Lecture I have nothing to

Henry Moon Lecture I have nothing to disclose Ovarian tumors in the young

gwas identifies three loci implicating the planar cell
GWAS identifies three loci, implicating

GWAS identifies three loci, implicating the planar cell polarity pathway and

iod
IOD IOD BAND Rethinking modular

IOD IOD BAND Rethinking modular design to harness the dynamics of live cell

synthesis and tumor cell growth inhibitory effects of new
Synthesis and Tumor Cell Growth

Synthesis and Tumor Cell Growth Inhibitory Effects of New Flavonosides and

tumor markers o tumor index substances released from the
TUMOR MARKERS o Tumor index substances

TUMOR MARKERS o Tumor index substances released from the tumor cells, which

p53
p53 TUMOR SUPPRESSOR PROTEIN AG

FUNCTIONS and REGULATION OF THE p53 TUMOR SUPPRESSOR PROTEIN AG Jochemsen

corporate presentation
Corporate Presentation H.C. Wainwright

Corporate Presentation H.C. Wainwright & Co. 21 st Annual Global

adrenergic receptors
ADRENERGIC RECEPTORS Extracellular S

1B 1B -Adrenoceptor phosphorylation. Adrenoceptor phosphorylation. Roles(s)

healey als platform trial
HEALEY ALS Platform Trial Sabrina

HEALEY ALS Platform Trial Sabrina Paganoni, MD, PhD Ben Saville, PhD Jinsy

ap1189 a new medicine to treat inflammatory diseases
AP1189 - A new medicine to treat

AP1189 - A new medicine to treat inflammatory diseases Thomas Jonassen, CSO

syncona capital
Syncona Capital Markets Day February

Syncona Capital Markets Day February 2020 synconaltd.com Image Freeline

5 30 18
5/30/18 Medical Cannabis: Operational

5/30/18 Medical Cannabis: Operational Issues (Training, Workforce,

corporate
CORPORATE PRESENTATION I. CORPORATE

OCTOBER 2019 CORPORATE PRESENTATION I. CORPORATE HIGHLIGHTS II.

to fight cancer
TO FIGHT CANCER 4Q 2019 11 March 2020

ACTIVATING THE PATIENTS IMMUNE SYSTEM TO FIGHT CANCER 4Q 2019 11 March 2020

annual general meeting
ANNUAL GENERAL MEETING MAY 29, 2020

ANNUAL GENERAL MEETING MAY 29, 2020 MANAGEMENT PRESENTATION LISTED EURONEXT

the cre luc reporter m ouse m odel
The CRE Luc Reporter M ouse M odel A

The CRE Luc Reporter M ouse M odel A transgenic bioimaging mouse model to

hyperkalemic periodic paralysis preliminary survey
Hyperkalemic Periodic Paralysis

Hyperkalemic Periodic Paralysis Preliminary Survey Results & Management

a
A lthough cross-national epidemiologic

Laurence J. Kirmayer Cultural Variations in the Clinical Presentation of